Skip to main content

Advertisement

SpringerLink
Log in

The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables

  • Original Paper
  • Published:
Journal of Molecular Histology Aims and scope Submit manuscript

Abstract

Ovarian cancer is the most common cause of death among all gynecologic malignancies and a result of complex interaction of multiple oncogenes and tumor suppressor genes. The aim of this study was to evaluate expression of HER-2/neu (c-erbB2), survivin and cycline D1 biomarkers in serous ovarian neoplasms and their correlations with clinicopathological variables in serous ovarian cancers. We analyzed pathological specimens of 62 patients with benign (n = 25), borderline (n = 14) and malignant (n = 23) serous ovarian neoplasms. Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded specimens. Significantly more immunoreactivity with HER-2/neu was detected in malignant tumors (100 %) compared to borderline (78.6 %) and benign tumors (48 %) (P < 0.01). Survivin expression was significantly higher in malignant tumors (91.3 %) than those found in borderline (71.4 %) and benign tumors (24 %) (P < 0.001). Similarly, higher cyclin D1 expression was observed in malignant tumors (95.6 %) compared to borderline (85.7 %) and benign tumors (48 %) (P < 0.001). Expression of all biomarkers analyzed significantly and gradually increased from benign to borderline and borderline to malignant serous tumors. In terms of clinicopathological variables, only tumor grade was associated with the expression of all biomarkers others exhibited different correlations in serous ovarian cancers. The expressions of HER-2/neu (c-erbB2), survivin and cycline D1 are positively correlated with the malignant potential of serous ovarian neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6:24

    Article  PubMed Central  PubMed  Google Scholar 

  • Altieri DC (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18(6):609–615

    Article  CAS  PubMed  Google Scholar 

  • Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921

    Article  CAS  PubMed  Google Scholar 

  • Barbieri F, Lorenzi P, Ragni N, Schettini G, Bruzzo C, Pedullà F et al (2004) Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 66(4):310–315

    Article  CAS  PubMed  Google Scholar 

  • Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A et al (2005) Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res Off J Am Assoc Cancer Res 11(16):6075–6086

    Article  CAS  Google Scholar 

  • Chen L, Liang L, Yan X, Liu N, Gong L, Pan S et al (2013) Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 23(2):256–263

    Article  Google Scholar 

  • Cui X, Liu Y, Wan C, Lu C, Cai J, He S, Ni T, Zhu J, Wei L, Zhang Y, Qian H (2014) Decreased expression of SERPINB1 correlates with tum or invasion and poor prognosis in hepatocellular carcinoma. J Mol Histol 45(1):59–68

    Article  CAS  PubMed  Google Scholar 

  • Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, Szafron L, Madry R, Murawska M et al (2011) Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res 4(1):20

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L et al (2005) Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 92(2):271–277

    CAS  PubMed Central  PubMed  Google Scholar 

  • FIGO (International Federation of Gynecology and Obstetrics) (2006) 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S1–S257

  • Goff BA, Mandel L, Muntz HG, Melancon CH (2000) Ovarian carcinoma diagnosis. Cancer 89(10):2068–2075

    Article  CAS  PubMed  Google Scholar 

  • Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ et al (2007) Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211(4):439–446

    Article  CAS  PubMed  Google Scholar 

  • Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF et al (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108(1):3–9

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakir C, Sensu S et al (2010) The relationship of c-erbB2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol 5:13

    Article  PubMed Central  PubMed  Google Scholar 

  • Heublein S, Vrekoussis T, Mayr D, Friese K, Lenhard M, Jeschke U et al (2013) Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). J Ovarian Res 6(1):6

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7(3):331–342

    Article  CAS  PubMed  Google Scholar 

  • Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G (1996) Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett 98(2):151–155

    Article  CAS  PubMed  Google Scholar 

  • Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A (2000) Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 6(6):529–534

    Article  CAS  PubMed  Google Scholar 

  • Kucukgoz Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A et al (2014) Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet 289(2):393–398

    Article  CAS  PubMed  Google Scholar 

  • Lanitis E, Dangaj D, Hagemann IS, Song D-G, Best A, Sandaltzopoulos R et al (2012) Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 7(11):e49829

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Li F, Ling X (2006) Survivin study: an update of « what is the next wave » ? J Cell Physiol 208(3):476–486

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Li W, Jiang H-R, Xu X-L, Wang J, Zhang J, Liu M-L et al (2010) Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo. Int J Mol Sci 11(10):3999–4013

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lin C-K, Chao T-K, Yu C-P, Yu M-H, Jin J-S (2009) The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS Acta Pathol Microbiol Immunol Scand 117(3):162–175

    Article  CAS  Google Scholar 

  • Liu Z, Wu X, Zhang F, Han L, Bao G, He X, Xu Z (2013) AhR expression is increased in hepatocellular carcinoma. J Mol Histol 44(4):455–461

    Article  CAS  PubMed  Google Scholar 

  • Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA (2006) EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100(1):101–106

    Article  CAS  PubMed  Google Scholar 

  • Nossov V, Amneus M, Su F, Lang J, Janco JMT, Reddy ST et al (2008) The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199(3):215–223

    Article  CAS  PubMed  Google Scholar 

  • Nowee ME, Dorsman JC, Piek JMJ, Kosma VM, Hämäläinen K, Verheijen RHM et al (2007) HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. Histopathology 51(5):666–673

    Article  CAS  PubMed  Google Scholar 

  • Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C et al (2008) HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 18(1):14–21

    Article  CAS  Google Scholar 

  • Qian X, Xi X, Li L (2011) Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem 19(2):126–132

    Article  CAS  Google Scholar 

  • Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 102(2):128–131

    Article  CAS  Google Scholar 

  • Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M, De la Garza-Salazar J (2006) Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2(3):180–190

    Article  Google Scholar 

  • Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M (2002) Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21(2):315–320

    CAS  PubMed  Google Scholar 

  • Sylvia MT, Kumar S, Dasari P (2012) The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol 55(1):33–37

    Article  PubMed  Google Scholar 

  • Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I (2002) Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int J Mol Med 10(2):211–216

    CAS  PubMed  Google Scholar 

  • Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K (2002) Survivin gene expression in endometriosis. J Clin Endocrinol Metab 87(7):3452–3459

    Article  CAS  PubMed  Google Scholar 

  • Uharcek P (2008) Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 34(5):776–783

    Article  PubMed  Google Scholar 

  • Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D (2006) HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer Off J Int Gynecol Cancer 16(5):1897–1902

    Article  CAS  Google Scholar 

  • Wheatley SP, McNeish IA (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247:35–88

    Article  CAS  PubMed  Google Scholar 

  • Worsley SD, Ponder BA, Davies BR (1997) Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 64(2):189–195

    Article  CAS  PubMed  Google Scholar 

  • Wu G-Q, Xie D, Yang G-F, Liao Y-J, Mai S-J, Deng H-X et al (2009) Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. Int J Cancer J Int Cancer 125(11):2631–2642

    Article  CAS  Google Scholar 

  • Wu Y-Y, Chen L, Wang G-L, Zhang Y-X, Zhou J-M, He S, Qin J, Zhu Y-Y (2013) Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF. J Mol Histol 44(4):433–445

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto H, Ngan CY, Monden M (2008) Cancer cells survive with survivin. Cancer Sci 99(9):1709–1714

    Article  CAS  PubMed  Google Scholar 

  • Yamashita S-I, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S et al (2007) Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27(4C):2803–2808

    CAS  PubMed  Google Scholar 

  • Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L et al (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci CMLS 59(8):1406–1412

    Article  CAS  Google Scholar 

  • Zaidi SK, Grandy RA, Lopez-Camacho C, Montecino M, van Wijnen AJ, Lian JB et al (2014) Bookmarking target genes in mitosis: a shared epigenetic trait of phenotypic transcription factors and oncogenes? Cancer Res 74(2):420–425

    Article  CAS  PubMed  Google Scholar 

  • Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor L-Y et al (2010) Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys 78(4):1095–1103

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Selcuk University, Konya, Turkey

    Gulay Turan & Lema Tavli

  2. Department of Gynecology and Obstetrics, Istanbul Medeniyet University, Istanbul, Turkey

    Ceyda Sancakli Usta

  3. Department of Gynecology and Obstetrics, Fatih Sultan Mehmet Education and Training Hospital, Istanbul, Turkey

    Akin Usta

  4. Department of Histology and Embriyology Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey

    Mehmet Kanter

  5. Department of Embryology, Yeni Yuzyil University, Istanbul, 34710, Turkey

    Meric Karacan

  6. Department of Gynecology and Obstetrics, Selcuk University, Konya, Turkey

    Cetin Celik

  7. Department of Medical Genetics, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey

    Metin Eser

Authors
  1. Gulay Turan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ceyda Sancakli Usta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akin Usta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Kanter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lema Tavli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meric Karacan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cetin Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Metin Eser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Kanter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turan, G., Usta, C.S., Usta, A. et al. The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables. J Mol Hist 45, 679–687 (2014). https://doi.org/10.1007/s10735-014-9591-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10735-014-9591-2

Keywords

Search

Navigation